Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
about
Pro-coagulant haemostatic factors for the prevention and treatment of bleeding in patients without haemophiliaProphylaxis in older Canadian adults with hemophilia A: lessons and more questionsRationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A.Understanding patient preferences and willingness to pay for hemophilia therapies.Tertiary prophylaxis in adults: is there a rationale?Factor VIII therapy for hemophilia A: current and future issues.Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.Individualizing prophylaxis in hemophilia: a review.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand.Prophylaxis in haemophilia should be life-long.Treatment adherence in hemophilia.Prophylaxis for adults with haemophilia: one size does not fit all.Prophylaxis for adults with haemophilia: towards a personalised approach?Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa.Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population.Hemophilia-Specific Quality of Life Index (Haemo-QoL and Haem-A-QoL questionnaires) of children and adults: result of a single center from Turkey.Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A.Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy.Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study.Adherence to clotting factors among persons with hemophilia A or B.National needs assessment of patients treated at the United States Federally-Funded Hemophilia Treatment Centers.Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study.Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.
P2860
Q24201587-1E944C73-2148-4739-A020-C1ADD0CADA33Q35091077-9B42983F-DFDE-4046-B4D5-030B02879FD2Q35311771-58FE1125-CC17-446B-810D-33A6CD37D87DQ36189452-FF25E25D-47BA-4E21-ACA3-17105D9D0599Q36284406-AD0C0028-A199-45B0-9257-39D2ABF3991BQ38013763-178A7929-3D74-486B-BD1F-E4B7C7AED04CQ38203350-5B208662-8CC3-4453-8B3F-095490C92394Q38205211-AD6C028D-F586-46FA-92E4-CEA7CBFC9447Q38323857-2B1E663B-17CC-4657-ACD3-004E428A43ECQ38574414-4E1D3CC3-58DD-4AC6-8D55-9656DBB7A440Q38764214-05109033-B9C3-46E2-A846-62FDF8E2134BQ41772358-DF777CAC-9198-4695-AFB1-C65C4FFEB07AQ42113961-AAAEE017-9ADC-4BCA-9C8B-270428843966Q42371331-BC23DE8F-7587-4D3A-8940-8F111B4045D4Q42555149-4B4E87CC-326F-46B5-84F9-E1DF6EA17666Q42555155-4A69D907-70FB-4ABE-BFA7-77BD7852BE20Q43088590-F3F5A181-F0B6-4C42-A301-41E5A8221622Q43938600-1E05B524-6DE9-46A2-986D-12787B0D87C7Q45862045-FCB7060A-1505-48E9-AB79-DAB707040539Q45862772-A4444C87-AEE8-4F6E-A021-C1BB62846769Q45864589-5A5A5CD8-55EB-4987-866E-DFBE118C786FQ45865289-59F608FE-22C6-4AD0-B246-FCB8812F8263Q45866634-F2E00006-F7DA-4BFC-88EC-C1DE0473B6DFQ45880326-C7520BF2-A91F-4BCE-8A5D-97BE3F833AEEQ45888176-BDAB61E0-1EA7-4224-A3E4-8FDC29C09317Q50195965-63BD0841-0645-4130-96BB-A6E06F48F4B6
P2860
Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Factor VIII prophylaxis for ad ...... ey of attitudes and practices.
@en
Factor VIII prophylaxis for ad ...... ey of attitudes and practices.
@nl
type
label
Factor VIII prophylaxis for ad ...... ey of attitudes and practices.
@en
Factor VIII prophylaxis for ad ...... ey of attitudes and practices.
@nl
prefLabel
Factor VIII prophylaxis for ad ...... ey of attitudes and practices.
@en
Factor VIII prophylaxis for ad ...... ey of attitudes and practices.
@nl
P921
P1433
P1476
Factor VIII prophylaxis for ad ...... ey of attitudes and practices.
@en
P2093
L A Valentino
P304
P356
10.1111/J.1365-2516.2009.02036.X
P577
2009-06-01T00:00:00Z